Amphastar Pharma (AMPH) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2016
August 8, 2016 4:06 PM EDTRANCHO CUCAMONGA, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended June 30, 2016.
Second Quarter Highlights
Net revenues of $68.0 million for the second quarterGAAP net income of $6.9 million, or $0.15 per diluted share for the second quarterAdjusted non-GAAP net income of $10.3 million, or $0.23 per diluted share for the second quarterDr. Jack Zhang, Amphastars CEO, commented:Â Resubmitting... More
